{
  "metadata": {
    "model": "gpt-4o",
    "prompt_name": "v2",
    "prompt_description": "Detailed summary with variant focus",
    "timestamp": "20260120_113622",
    "num_pmcids": 3,
    "citations_file": null
  },
  "summaries": [
    {
      "pmcid": "PMC5508045",
      "summary": "## Overview\nThis study investigates the influence of genetic and non-genetic factors on the variability of stable warfarin doses in a cohort of 250 Thai patients. Warfarin, a commonly used anticoagulant, has a narrow therapeutic index and significant inter-individual variability in dose requirements, which can lead to complications if not properly managed. The study focuses on four genetic polymorphisms: VKORC1 − 1639G > A, CYP2C9*3, CYP4F2 rs2108622, and UGT1A1 rs887829, alongside non-genetic factors such as age, body mass index (BMI), and concomitant medication use.\n\n## Variant-Specific Findings\n\n### VKORC1 − 1639G > A (rs9923231)\nThe VKORC1 − 1639G > A polymorphism was found to be a major determinant of warfarin dose requirements. Patients with the AA genotype required significantly lower stable weekly doses (SWDs) of warfarin compared to those with the GG genotype, with a reduction of 49.7% in dose (p < 0.001). The GA genotype also required a lower dose, with a 27.7% reduction. This variant alone accounted for 26.2% of the variability in warfarin dosing, making it a critical factor in dose determination. Clinically, genotyping for VKORC1 − 1639G > A can guide initial dosing and reduce the risk of adverse events.\n\n### CYP2C9*3 (rs1057910)\nThe CYP2C9*3 variant also significantly influenced warfarin dosing. Patients with the *3/*3 genotype required 64.6% lower doses, and those with the *1/*3 genotype required 34.1% lower doses compared to the *1/*1 genotype (p = 0.006). This variant explained about 6.0% of the dose variability. Given its impact on warfarin metabolism, testing for CYP2C9*3 can be valuable in personalizing warfarin therapy, particularly in populations with a higher prevalence of this allele.\n\n### CYP4F2 rs2108622\nThe CYP4F2 rs2108622 TT genotype was associated with a modest increase in warfarin dose requirements, contributing to 1.2% of the dose variability. Although the effect size is smaller compared to VKORC1 and CYP2C9, it remains statistically significant (p = 0.016). This variant's role in vitamin K metabolism suggests that it could be considered in comprehensive pharmacogenomic testing, especially in patients with unexplained dose variability.\n\n### UGT1A1 rs887829\nThe UGT1A1 rs887829 polymorphism did not show a significant association with warfarin dose variability in this study (p = 0.921). Despite previous reports of its impact in other populations, this variant does not appear to be clinically actionable in the Thai cohort studied. Therefore, routine testing for UGT1A1 rs887829 may not be necessary for warfarin dosing in this population.\n\n## Summary and Recommendations\nThe study highlights the significant role of VKORC1 − 1639G > A and CYP2C9*3 polymorphisms in determining warfarin dose requirements, with CYP4F2 rs2108622 having a minor but notable effect. These findings underscore the importance of incorporating genetic testing into clinical practice to optimize warfarin therapy, reduce adverse events, and improve patient outcomes. While UGT1A1 rs887829 does not appear to influence dosing in this population, further research could explore its role in other ethnic groups. Clinicians should consider both genetic and non-genetic factors, such as age and BMI, when prescribing warfarin to achieve a more precise and safe anticoagulation therapy.",
      "num_variants": 4,
      "variants": [
        "rs9923231",
        "rs1057910",
        "rs2108622",
        "rs887829"
      ]
    },
    {
      "pmcid": "PMC4916189",
      "summary": "## Overview\nThe ENCORE1 study evaluated the pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz (EFV) at doses of 400 mg and 600 mg in treatment-naïve HIV-infected patients over 96 weeks. The study aimed to assess the impact of genetic polymorphisms on the efficacy and safety of EFV, particularly focusing on the relationship between EFV plasma concentrations and virological suppression, as well as the occurrence of adverse events.\n\n## Variant-Specific Findings\n\n### CYP2B6 Variants\n- **CYP2B6 516G>T (rs3745274):** Patients with GT or TT genotypes had an increased likelihood of discontinuation due to adverse events compared to those with the GG genotype. The hazard ratio (HR) for discontinuation was 1.80 for GT and 2.66 for TT, indicating a significant increase in risk (p = 0.010). However, this variant was not associated with virological response, suggesting that while it affects drug tolerability, it does not impact efficacy.\n  \n- **CYP2B6 983T>C (rs28399499):** Carriers of the TC or CC genotypes had a decreased risk of central nervous system (CNS) adverse events compared to TT carriers, with an odds ratio (OR) of 0.30 (p = 0.010). This suggests a protective effect against CNS toxicity, potentially due to altered metabolism of EFV.\n\n- **CYP2B6 15582C>T (rs4803419):** Individuals with CT or TT genotypes were at a higher risk of CNS-related adverse events compared to those with the CC genotype, with an OR of 1.59 (p = 0.011). This indicates that these variants may predispose patients to CNS toxicity when treated with EFV.\n\n### ABCB1 Variant\n- **ABCB1 3435C>T (rs1045642):** The TT genotype was associated with a significantly increased risk of CNS adverse events, with an OR of 2.14 (p = 0.006). This variant may affect the efflux of EFV or its metabolites across the blood-brain barrier, leading to higher CNS exposure and toxicity.\n\n### NR1I2 Variant\n- **NR1I2 63396C>T (rs2472677):** The TT genotype was associated with a decreased likelihood of EFV discontinuation, with a HR of 0.22 (p = 0.008). This suggests that this variant may enhance drug tolerability, possibly through effects on drug metabolism or transport.\n\n## Summary and Recommendations\nThe ENCORE1 study highlights the significant role of genetic polymorphisms in influencing the safety profile of efavirenz, particularly regarding CNS adverse events and treatment discontinuation. Variants in CYP2B6 and ABCB1 were notably associated with increased CNS toxicity, while NR1I2 variants appeared to improve drug tolerability. Clinicians should consider genotyping for these variants in patients who experience adverse effects with EFV, as this information could guide dose adjustments or alternative therapy choices. The findings support the use of EFV 400 mg as a viable option to reduce toxicity while maintaining efficacy, especially in resource-limited settings where genotyping may not be feasible.",
      "num_variants": 7,
      "variants": [
        "CYP2B6*1",
        "CYP2B6*9",
        "rs3745274",
        "rs2472677",
        "rs1045642",
        "rs28399499",
        "rs4803419"
      ]
    },
    {
      "pmcid": "PMC12036300",
      "summary": "## Overview\nThis study investigates the impact of CYP2C19 genetic variants on the clinical efficacy of a doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The research focuses on the prevalence of CYP2C19*2, *3, and *17 alleles and their association with major acute cardiovascular events (MACE) and bleeding complications. The study aims to provide insights into optimizing antiplatelet therapy based on genetic profiles.\n\n## Variant-Specific Findings\n\n### CYP2C19*2\nThe CYP2C19*2 allele, a well-known loss-of-function variant, was found in 8% of the study population. Despite its association with reduced clopidogrel activation, the study found no significant association between CYP2C19*2 carrier status and an increased risk of MACE in patients treated with a doubled maintenance dose of clopidogrel (150 mg/day). This suggests that increasing the clopidogrel dose may mitigate the reduced efficacy typically associated with this allele. The findings align with recommendations from pharmacogenetic guidelines that suggest dose adjustments for intermediate metabolizers to achieve adequate platelet inhibition.\n\n### CYP2C19*3\nThe CYP2C19*3 allele was not detected in the study population, which is consistent with its low prevalence in non-Asian populations. As such, no clinical associations or recommendations could be derived for this variant within the context of this study.\n\n### CYP2C19*17\nThe CYP2C19*17 allele, a gain-of-function variant, was present in 17% of the participants. Although carriers of this allele are generally at an increased risk of bleeding due to enhanced clopidogrel activation, the study did not find a statistically significant increase in bleeding events among carriers treated with the doubled dose. This suggests that the increased dose does not exacerbate bleeding risk in this population, although the small sample size warrants cautious interpretation. The clinical actionability of this finding remains uncertain, and further research is needed to confirm these results.\n\n## Summary and Recommendations\nThe study concludes that a doubled maintenance dose of clopidogrel may effectively counteract the reduced efficacy associated with the CYP2C19*2 allele in Syrian patients undergoing PCI, without significantly increasing bleeding risk in CYP2C19*17 carriers. These findings support the potential for genotype-guided dosing strategies to optimize clopidogrel therapy. However, due to the study's limited sample size, larger studies are necessary to validate these observations and refine clinical guidelines. Healthcare professionals should consider genetic testing for CYP2C19 variants to tailor antiplatelet therapy, particularly in populations with similar genetic backgrounds.",
      "num_variants": 3,
      "variants": [
        "CYP2C19*1",
        "CYP2C19*2",
        "CYP2C19*17"
      ]
    }
  ]
}